PLK1 phosphorylates PAX3-FOXO1, the inhibition of which triggers regression of alveolar Rhabdomyosarcoma.

Pediatric tumors harbor very low numbers of somatic mutations and therefore offer few targets to improve therapeutic management with targeted drugs. In particular, outcomes remain dismal for patients with metastatic alveolar rhabdomyosarcoma (aRMS), where the chimeric transcription factor PAX3/7-FOXO1 has been implicated but problematic to target. In this report, we addressed this challenge by developing a two-armed screen for druggable upstream regulatory kinases in the PAX3/7-FOXO1 pathway. Screening libraries of kinome siRNA and small molecules, we defined PLK1 as an upstream-acting regulator. Mechanistically, PLK1 interacted with and phosphorylated PAX3-FOXO1 at the novel site S503, leading to protein stabilization. Notably, PLK1 inhibition led to elevated ubiquitination and rapid proteasomal degradation of the PAX3-FOXO1 chimeric oncoprotein. On this basis, we embarked on a preclinical validation of PLK1 as a target in a xenograft mouse model of aRMS, where the PLK1 inhibitor BI 2536 reduced PAX3-FOXO1-mediated gene expression and elicited tumor regression. Clinically, analysis of human aRMS tumor biopsies documented high PLK1 expression to offer prognostic significance for both event-free survival and overall survival. Taken together, these preclinical studies validate the PLK1-PAX3-FOXO1 axis as a rational target to treat aRMS.

[1]  Xinyu Tang Log-Rank Test , 2014 .

[2]  C. Keller,et al.  PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma , 2014, Proceedings of the National Academy of Sciences.

[3]  G. Getz,et al.  Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. , 2014, Cancer discovery.

[4]  Chengfu Yuan,et al.  The function of FOXO1 in the late phases of the cell cycle is suppressed by PLK1-mediated phosphorylation , 2014, Cell cycle.

[5]  S. Keir,et al.  Initial testing (stage 1) of the polo‐like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program , 2014, Pediatric blood & cancer.

[6]  C. Keller,et al.  Cell-Cycle Dependent Expression of a Translocation-Mediated Fusion Oncogene Mediates Checkpoint Adaptation in Rhabdomyosarcoma , 2014, PLoS genetics.

[7]  Heather L. Mulder,et al.  Targeting oxidative stress in embryonal rhabdomyosarcoma. , 2013, Cancer cell.

[8]  N. Ahmad,et al.  The role of polo-like kinase 1 in carcinogenesis: cause or consequence? , 2013, Cancer research.

[9]  C. Keller,et al.  Small Molecule Inhibition of PAX3-FOXO1 through AKT Activation Suppresses Malignant Phenotypes of Alveolar Rhabdomyosarcoma , 2013, Molecular Cancer Therapeutics.

[10]  S. Fulda,et al.  Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. , 2013, Cancer letters.

[11]  M. Valenti,et al.  Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo , 2013, Clinical Cancer Research.

[12]  Qiang Yu,et al.  PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. , 2013, Cancer discovery.

[13]  Yu Xue,et al.  Systematic analysis of the Plk-mediated phosphoregulation in eukaryotes , 2013, Briefings Bioinform..

[14]  F. Barr,et al.  Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Research: Utility and Pitfalls , 2013, Front. Oncol..

[15]  F. Barr,et al.  A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma , 2013, Expert opinion on therapeutic targets.

[16]  O. Delattre,et al.  P-cadherin is a direct PAX3–FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness , 2013, Oncogene.

[17]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[18]  S. Ong,et al.  Cyclin-Dependent Kinase 4 Phosphorylates and Positively Regulates PAX3-FOXO1 in Human Alveolar Rhabdomyosarcoma Cells , 2013, PloS one.

[19]  G. Grosveld,et al.  PAX3‐FOXO1 and FGFR4 in alveolar rhabdomyosarcoma , 2012, Molecular carcinogenesis.

[20]  S. Knapp,et al.  Rapid determination of multiple linear kinase substrate motifs by mass spectrometry. , 2012, Chemistry & biology.

[21]  Mauro Delorenzi,et al.  PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  K. Schaefer,et al.  Prognostic value of PAX–FKHR fusion status in alveolar rhabdomyosarcoma: A report from the cooperative soft tissue sarcoma study group (CWS) , 2010, Pediatric blood & cancer.

[23]  T. Triche,et al.  Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas , 2009, Molecular Cancer Therapeutics.

[24]  B. Schäfer,et al.  Immunohistochemical detection of EGFR, fibrillin‐2, P‐cadherin and AP2β as biomarkers for rhabdomyosarcoma diagnostics , 2009, Histopathology.

[25]  G. Adolf,et al.  BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity , 2009, Clinical Cancer Research.

[26]  C. Linardic PAX3-FOXO1 fusion gene in rhabdomyosarcoma. , 2008, Cancer letters.

[27]  D. Fabbro,et al.  Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities. , 2008, Cancer research.

[28]  H. Hosoi,et al.  Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. , 2008, Biochemical and biophysical research communications.

[29]  B. Schäfer,et al.  Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR , 2007, Oncogene.

[30]  A. Hollenbach,et al.  The oncogenic fusion protein Pax3-FKHR has a greater post-translational stability relative to Pax3 during early myogenesis. , 2007, Biochimica et biophysica acta.

[31]  A. Olshen,et al.  Global gene expression profiling of PAX‐FKHR fusion‐positive alveolar and PAX‐FKHR fusion‐negative embryonal rhabdomyosarcomas , 2007, The Journal of pathology.

[32]  Péter Lénárt,et al.  BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo , 2007, Current Biology.

[33]  J. Peters,et al.  The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1 , 2007, Current Biology.

[34]  T. Triche,et al.  Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. , 2006, Cancer research.

[35]  Cesare Furlanello,et al.  Gene expression profiling identifies potential relevant genes in alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3‐FKHR positive and negative tumors , 2006, International journal of cancer.

[36]  A. Ullrich,et al.  Targeting polo-like kinase 1 for cancer therapy , 2006, Nature Reviews Cancer.

[37]  B. Shneiderman,et al.  Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. , 2006, Brain : a journal of neurology.

[38]  Silvia Behnke,et al.  Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  P. Bühlmann,et al.  Gene Expression Signatures Identify Rhabdomyosarcoma Subtypes and Detect a Novel t(2;2)(q35;p23) Translocation Fusing PAX3 to NCOA1 , 2004, Cancer Research.

[40]  P. Sorensen,et al.  PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  P. Cohen,et al.  Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion , 2002, The EMBO journal.

[42]  C. Berking,et al.  Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene. , 2000, Cancer research.

[43]  B. Schäfer,et al.  Molecular features of a human rhabdomyosarcoma cell line with spontaneous metastatic progression , 2000, British Journal of Cancer.

[44]  L. Peso,et al.  Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt , 1999, Oncogene.

[45]  B. Schäfer,et al.  PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma , 1999, Oncogene.

[46]  E. Sausville,et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.

[47]  M. Bittner,et al.  Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. , 1998, Cancer research.

[48]  R. Davis,et al.  Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[49]  B. Schäfer,et al.  Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[50]  F. Barr,et al.  Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[51]  T. Karn,et al.  Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[52]  P. Meltzer,et al.  Cancer esearch cular and Cellular Pathobiology ome-Wide Identification of PAX 3-FKHR Binding Sites in bdomyosarcoma Reveals Candidate Target Genes R ortant for Development and Cancer , 2010 .

[53]  Y. Sekido,et al.  Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer , 2010 .

[54]  James R. Anderson,et al.  Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.